Skip to content

Multi-Center Registration of Wake-Up Stroke in China (MCRWUSC)

Multi-Center Registration of Wake-Up Stroke in China (MCRWUSC)

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100049133
Enrollment
Unknown
Registered
2021-07-21
Start date
2019-01-01
Completion date
Unknown
Last updated
2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute ischemic stroke

Interventions

Antiplatelet-Statins-Antihypertensive Group:Antiplatelet-Statins-Antihypertensive

Sponsors

Department of Neurology, Shanghai Pudong Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged 18-80 years; 2. First-episode patients with acute ischemic stroke.(in accordance with the diagnostic criteria of Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2018); 3. Last known well (without neurological symptoms)>4.5hours of treatment initiation. Measurable disabling; neurological deficit (defined as an impairment of one or more of the following: language, motor function, cognition, gaze, vision, neglect); 4. The time from onset to enrolment was less than 24 hours, and stroke onset was defined as the midway point between the sleep onset (or last known normal) and wake time(refer to Int J Stroke. 2012 Jan;7(1):74-80.); 5. Patients who signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Asymptomatic territorial infarction; 2. Patients who declined participation in registration and follow-up investigation; The completed cases included all registration data of patients for 90 days+/-7 days. Patients presenting with one or more of the following conditions would be withdrawn from this study: 1) Patients dissatisfied the inclusion criteria; 2) The patients withdrew the informed consent form; 3) Any situation where the investigators believed that the patients should discontinue from this study for safety reasons or in the interest of the patients4) Patients were lost to follow-up; 5) Others. On termination of the study, patients should be assessed for endpoints. except for patients lost to follow-up.

Design outcomes

Primary

MeasureTime frame
Modified Rankin Scale (mRS);NIHSS;

Secondary

MeasureTime frame
the Barthelindex (BI);

Countries

China

Contacts

Public ContactShuangxing Hou

Shanghai Pudong Hospital (Fudan University Pudong Medical Center)

housx021@163.com18117209852

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 11, 2026